Nanoparticle-based mobile biosensors for the rapid detection of sepsis biomarkers in whole blood

Alba-Patiño, Alejandra; Russell, Steven M.; Borges, Marcio; Pazos-Pérez, Nicolás; Álvarez‐Puebla, Ramón A.; Rica, Roberto de la

doi:10.1039/d0na00026d

Cited by 57 publications

(56 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In turn, this could be used for guiding the timing and dosage of antiinflammatory treatments, as well as to assess their effectiveness. Point-of-care diagnostic devices will likely be crucial to enable these kinetic biomarker measurements without collapsing central diagnosis laboratories (74)(75)(76)(77).…”

Section: Resultsmentioning

confidence: 99%

COVID-19: In the Eye of the Cytokine Storm

2020

Self Cite

View full text Add to dashboard Cite

The dysregulated release of cytokines has been identified as one of the key factors behind poorer outcomes in COVID-19. This "cytokine storm" produces an excessive inflammatory and immune response, especially in the lungs, leading to acute respiratory distress (ARDS), pulmonary edema and multi-organ failure. Alleviating this inflammatory state is crucial to improve prognosis. Pro-inflammatory factors play a central role in COVID-19 severity, especially in patients with comorbidities. In these situations, an overactive, untreated immune response can be deadly, suggesting that mortality in COVID-19 cases is likely due to this virally driven hyperinflammation. Administering immunomodulators has not yielded conclusive improvements in other pathologies characterized by dysregulated inflammation such as sepsis, SARS-CoV-1, and MERS. The success of these drugs at reducing COVID-19-driven inflammation is still anecdotal and comes with serious risks. It is also imperative to screen the elderly for risk factors that predispose them to severe COVID-19. Immunosenescence and comorbidities should be taken into consideration. In this review, we summarize the latest data available about the role of the cytokine storm in COVID-19 disease severity as well as potential therapeutic approaches to ameliorate it. We also examine the role of inflammation in other diseases and conditions often comorbid with COVID-19, such as aging, sepsis, and pulmonary disorders. Finally, we identify gaps in our knowledge and suggest priorities for future research aimed at stratifying patients according to risk as well as personalizing therapies in the context of COVID19-driven hyperinflammation.

show abstract

Section: Resultsmentioning

confidence: 99%

COVID-19: In the Eye of the Cytokine Storm

2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since IL-6 is released during the initial stages of an infection, it can be utilized as a biomarker to assist healthcare professionals in early identification of critically ill COVID-19 patients. Typically, the detection of IL-6 is performed using standard ELISA; 119 however, the FDA has issued an EUA for the Elecsys IL-6 immunoassay (June 2020), developed by Roche (Basel, Switzerland), for the quantitative detection of IL-6 in serum or plasma collected from COVID-19 patients ( Table S1 ). In this assay, patient serum or plasma is incubated with a biotinylated monoclonal IL-6-specific antibody (Ab1), followed by incubation with a monoclonal IL-6-specific antibody tagged with a ruthenium complex (Ab2) and streptavidin-coated magnetic microparticles (MPs) to form a sandwich conjugate (MP-Ab1-Ag-Ab2), which is then placed at an electrode using an external magnet.…”

Section: Patient Response Biomarker Testingmentioning

confidence: 99%

“…This assay demonstrated an LOD of 12.5 pg/mL using IL-6 spiked blood with an assay duration of 18 min. 119 …”

Section: Patient Response Biomarker Testingmentioning

confidence: 99%

Roadmap to the Bioanalytical Testing of COVID-19: From Sample Collection to Disease Surveillance

et al. 2020

View full text Add to dashboard Cite

The disease caused by SARS-CoV-2, coronavirus disease 2019 (COVID-19), has led to a global pandemic with tremendous mortality, morbidity, and economic loss. The current lack of effective vaccines and treatments places tremendous value on widespread screening, early detection, and contact tracing of COVID-19 for controlling its spread and minimizing the resultant health and societal impact. Bioanalytical diagnostic technologies have played a critical role in the mitigation of the COVID-19 pandemic and will continue to be foundational in the prevention of the subsequent waves of this pandemic along with future infectious disease outbreaks. In this Review, we aim at presenting a roadmap to the bioanalytical testing of COVID-19, with a focus on the performance metrics as well as the limitations of various techniques. The state-of-the-art technologies, mostly limited to centralized laboratories, set the clinical metrics against which the emerging technologies are measured. Technologies for point-of-care and do-it-yourself testing are rapidly emerging, which open the route for testing in the community, at home, and at points-of-entry to widely screen and monitor individuals for enabling normal life despite of an infectious disease pandemic. The combination of different classes of diagnostic technologies (centralized and point-of-care and relying on multiple biomarkers) are needed for effective diagnosis, treatment selection, prognosis, patient monitoring, and epidemiological surveillance in the event of major pandemics such as COVID-19.

show abstract

“…13 The nanoparticles were stabilized against salt-induced aggregation by substituting citrate molecules on their surface for thiol-PEG-acid ligands, and the resulting carboxylate moieties were used to covalently bind avidin molecules through amidation (EDC/ sulfo-NHS coupling) with a previously described method. 13 Antibody-decorated nanoparticles were obtained by adding 10 µL of biotinylated antibodies (4-5 mg mL −1 ) to 100 µL of avidin-modified gold nanoparticles ([Au] = 125 mM) for 1 hour. 12 When required, biotin-PEG was added at final concentration of 0.1 mM in order to block free avidin binding sites.…”

Section: Biosensor Fabricationmentioning

confidence: 99%

“…Finally, the pixel intensity is quantified with a mobile app previously developed in our laboratory. 13 The app automatically finds the region of interest and compensates for changes in illumination while at the same time guiding the user to the correct positioning of the smartphone with respect to the paper biosensor, all within a few seconds (Fig. 1D).…”

Section: Introductionmentioning

confidence: 99%

Mobile origami immunosensors for the rapid detection of urinary tract infections

Adrover-Jaume

Rojo-Molinero

Clemente

et al. 2020

Analyst

Self Cite

View full text Add to dashboard Cite

show abstract

Nanoparticle-based mobile biosensors for the rapid detection of sepsis biomarkers in whole blood

Abstract: Detecting small variations in the levels of IL-6 is crucial for the early diagnosis of sepsis.

Cited by 57 publications

References 30 publications

COVID-19: In the Eye of the Cytokine Storm

COVID-19: In the Eye of the Cytokine Storm

Roadmap to the Bioanalytical Testing of COVID-19: From Sample Collection to Disease Surveillance

Mobile origami immunosensors for the rapid detection of urinary tract infections

Contact Info

Product

Resources

About